Evaluation of Corneal Cross-Linking As Adjuvant Therapy for the Management of Fungal Keratitis
Anji Wei,Kaidi Wang,Yan Wang,Lan Gong,Jianjiang Xu,Tingting Shao
DOI: https://doi.org/10.1007/s00417-019-04314-1
2019-01-01
Graefe s Archive for Clinical and Experimental Ophthalmology
Abstract:PurposeTo evaluate the efficacy of corneal cross-linking (CXL) as adjuvant therapy for the treatment of fungal ulcerative keratitis.MethodsForty-one patients with fungal ulcerative keratitis were recruited and assigned into two randomized controlled groups. These groups were treated with CXL combined with antifungal medications (CXL-M) or antifungal medications alone (M). The ulcers were assessed by slit-lamp biomicroscopy, slit-lamp images, in vivo confocal microscopy (IVCM), and anterior segment optical coherence tomography (AS-OCT). The patients were followed up before surgery/first visit (FV), 1day after surgery, 1 and 2weeks, and 1, 2, 3, 4, 5, and 6months after surgery/FV.ResultsIn the cured patients, the area of corneal ulcers, the duration of ulcer healing, the time to non-observed fungal hyphae by IVCM, the number of antifungal medications, the frequency of administered medications, and the maximum ulcer depth decreased significantly after CXL (all P<0.05) compared with the M group. There were no significant differences in either corneal thickness or epithelial thickness of ulcers after healing between 5 and 6months after surgery in the CXL-M group, while these were increased significantly at 6months compared with 5months after FV in the M group (both P<0.05).ConclusionsIn our study, CXL accelerated healing of the fungal ulcers, shortened the treatment duration, and minimized the need for medications and surgery. It appears that CXL is an effective procedure and adjuvant therapy for managing fungal keratitis.